Symptomatic sinus bradycardia associated with donepezil

被引:24
作者
Calvo-Romero, JM [1 ]
Ramos-Salado, JL [1 ]
机构
[1] Hosp Reg Univ Infanta Cristina, Med Interna Serv, Badajoz, Spain
关键词
Alzheimer's disease; bradycardia; dementia; donepezil;
D O I
10.33588/rn.2811.99025
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction. Donepezil is a drug which is being used more and more winery in mild-moder ate Alzheimer's disease. In general, it is well tolerated and the side-effects are basically cholinergic-dependent. Symptomatic disorders of cardiac rhythm associated with the use of donepezil are extremely unusual. Clinical case. We describe the case of an 81 year old patient with hypertensive cardiopathy, who developed sinus bradycardia, fainting and left cardiac failure three weeks after starting treatment with donepezil. When donepezil was stopped the sinus bradycardia disappeared a 24 hour electrocardiographic holter showed no signs of sinus none disease and no episodes of this type occurred during the following six months. Conclusion. Symptomatic sinus bradycardia is a possible adverse effect of treatment with donepezil in Alzheimer's disease.
引用
收藏
页码:1070 / 1072
页数:3
相关论文
共 18 条
[1]   Donepezil use in Alzheimer disease [J].
Barner, EL ;
Gray, SL .
ANNALS OF PHARMACOTHERAPY, 1998, 32 (01) :70-77
[2]   ALZHEIMERS-DISEASE - A DISORDER OF CORTICAL CHOLINERGIC INNERVATION [J].
COYLE, JT ;
PRICE, DL ;
DELONG, MR .
SCIENCE, 1983, 219 (4589) :1184-1190
[3]   TACRINE - 1ST DRUG APPROVED FOR ALZHEIMERS-DISEASE [J].
CRISMON, ML .
ANNALS OF PHARMACOTHERAPY, 1994, 28 (06) :744-751
[4]  
DAVIES P, 1976, LANCET, V2, P1403
[5]  
DOUCETTE R, 1986, CAN J NEUROL SCI, V13, P435
[6]   MEMORY AND COGNITIVE FUNCTION IN MAN - DOES CHOLINERGIC SYSTEM HAVE A SPECIFIC ROLE [J].
DRACHMAN, DA .
NEUROLOGY, 1977, 27 (08) :783-790
[7]   A 30-WEEK RANDOMIZED CONTROLLED TRIAL OF HIGH-DOSE TACRINE IN PATIENTS WITH ALZHEIMERS-DISEASE [J].
KNAPP, MJ ;
KNOPMAN, DS ;
SOLOMON, PR ;
PENDLEBURY, WW ;
DAVIS, CS ;
GRACON, SI ;
APTER, JT ;
LAZARUS, CN ;
BAKER, KE ;
BARNETT, M ;
BAUMEL, B ;
EISNER, LS ;
CASTELLS, B ;
BOLOURI, R ;
BENNETT, D ;
FORCHETTI, C ;
LEVIN, A ;
BLASS, JP ;
NOLAN, KA ;
GAINES, ER ;
RELKIN, N ;
BORISON, RL ;
DIAMOND, B ;
CELESIA, GG ;
ROSS, AP ;
DEXTER, J ;
DOODY, R ;
LIPSCOMB, L ;
KREITER, K ;
DUBOFF, EA ;
BLOCK, P ;
MARSHALL, D ;
WESTERGAARD, N ;
EARL, NL ;
WYNE, SV ;
HINMANSMITH, E ;
FARLOW, M ;
HENDRIE, HC ;
CARESS, JA ;
FARMER, M ;
HARPER, JE ;
FERGUSON, J ;
FOSTER, NL ;
BARBAS, NR ;
BLUEMLEIN, LA ;
GELB, DJ ;
BERENT, S ;
GIORDANI, B ;
GREENWALD, M ;
BERGMAN, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (13) :985-991
[8]  
Landsberg L., 1998, HARRISONS PRINCIPLES, P430
[9]   Medical treatment of Alzheimer disease [J].
Lopez-Pousa, S ;
Serra-Mestres, J .
REVISTA DE NEUROLOGIA, 1998, 26 (154) :1054-1060
[10]  
MIHARA M, 1993, INT J CLIN PHARM TH, V31, P223